When the Food and Drug Administration (FDA or the Agency) held a public hearing on the use of the internet and social media to promote regulated products, many in the industry were hopeful we would soon have clear direction on how to evolve our communications for the digital age. Nearly five years later, we’re still waiting for that guidance to be complete. Just recently, FDA released two draft guidance documents, the latest in a series on various elements of digital engagement bringing the total to four out of an expected five.
The last piece of draft guidance the Agency has committed to releasing this year (though it has already missed the July 9 deadline set forth in the 2012 FDA Safety and Innovation Act) is related to the use of links in product promotional content in social media.
A number of industry commentators and media outlets have already covered the details of the latest FDA social media guidance documents. Rather than reiterate the same points about these two, we’ve taken a step back and pulled out the key pieces from all four to help guide clients in the drug and device industries as they continue to navigate the new media landscape.
For more information, please contact Josh Baldwin - firstname.lastname@example.org. Share your feedback with us on twitter @msl_group